These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 14654535

  • 1. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
    Giannopoulos A, Constantinides C, Fokaeas E, Stravodimos C, Giannopoulou M, Kyroudi A, Gounaris A.
    Clin Cancer Res; 2003 Nov 15; 9(15):5550-8. PubMed ID: 14654535
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Nov 15; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 3. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May 15; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)].
    Villaronga A, Bellver E, Perli G, Pautaso O, Bengochea D, Roldán RA, Podskubska O, Belén R, Delgado G, Laberti O, Lando R, Rey H, Bengio R, Minuzzi L, Goldman E, Milman A, Sanguinetti O, Wernert O.
    Arch Esp Urol; 1996 Mar 15; 49(2):133-8. PubMed ID: 8702323
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug 15; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 10. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
    Kuroda K, Ishii N, Fukasawa K, Shirai M, Tajima M, Matsushima M, Miura K, Takanami M, Matsuhashi M, Kuwabara T, Matsumoto H, Sugita M.
    Hinyokika Kiyo; 1998 Aug 15; 44(8):547-52. PubMed ID: 9783189
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C, Sato K, Kato T.
    BJU Int; 2004 Aug 15; 94(3):317-21. PubMed ID: 15291859
    [Abstract] [Full Text] [Related]

  • 14. [Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
    Kumamoto Y, Tsukamoto T, Tamiya T, Takatsuka K, Furuya S, Yokoyama E, Honma A, Aoyama T, Tanda H, Kato S.
    Hinyokika Kiyo; 1985 Oct 15; 31(10):1861-83. PubMed ID: 2418659
    [Abstract] [Full Text] [Related]

  • 15. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
    Serretta V, Morgia G, Altieri V, Di Lallo A, Ruggiero G, Salzano L, Battaglia M, Falsaperla M, Zito A, Sblendorio D, Melloni D, Allegro R, members of Gruppo Studi Tumori Urologici (GSTU) Foundation.
    BJU Int; 2010 Jul 15; 106(2):212-7. PubMed ID: 20070299
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
    Pérez Mestre M, Cuñat Albert E, Francisco Mingol V, Arrufat Boix JM, Gallego Gómez J.
    Arch Esp Urol; 1999 May 15; 52(4):345-50. PubMed ID: 10380324
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.